BioSig Technologies, a medical technology company commercializing a proprietary biomedical signal processing platform, has filed for consideration with the FDA under the Coronavirus Treatment Acceleration Program (CTAP) for Vicromax, an orally administered drug that could be delivered to patients during all stages of Covid-19 – early-stage right when the patient starts to feel symptoms, mid-stage, or even late-stage while in the ICU. Earlier in the week, the company announced that the Mayo Clinic will be conducting Phase II trials for Vicromax in patients with Covid-19.    

Vicromax is an oral anti-viral treatment that has shown to have positive effects against the novel Coronavirus. In a laboratory setting at the Galveston National Laboratory in Texas, Vicromax was added to a tissue culture assay for SARS-CO-2 coronavirus and an anti-viral effect was observed, which led to a reduction of 98% of the infectious viruses.